Stimulator of InterferoN Genes (STING)-Associated Vasculopathy with Onset in Infancy Syndrome (SAVI) Associated with Disseminated Molluscum Contagiosum Under Baricitinib Treatment
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Liu, Y.; Jesus, A.A.; Marrero, B.; Yang, D.; Ramsey, S.E.; Sanchez, G.A.M.; Tenbrock, K.; Wittkowski, H.; Jones, O.Y.; Kuehn, H.S.; et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 2014, 371, 507–518. [Google Scholar] [PubMed]
- Volpi, S.; Insalaco, A.; Caorsi, R.; Santori, E.; Messia, V.; Sacco, O.; Terheggen-Lagro, S.; Cardinale, F.; Scarselli, A.; Pastorino, C.; et al. Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome. J. Clin. Immunol. 2019, 39, 476–485. [Google Scholar] [PubMed]
- Dai, Y.; Liu, X.; Zhao, Z.; He, J.; Yin, Q. Stimulator of Interferon Genes-Associated Vasculopathy with Onset in Infancy: A Systematic Review of Case Reports. Front. Pediatr. 2020, 8, 577918. [Google Scholar]
- Mendonça, L.O.; Frémond, M.L. Interferonopathies: From concept to clinical practice. Best Pract. Res. Clin. Rheumatol. 2024, 38, 101975. [Google Scholar] [PubMed]
- Kretzschmar, G.; Páez, L.P.; Tan, Z.; Wang, J.; Gonzalez, L.; Mugabo, C.H.; Johnsson, A.; Chen, Y.; Mikeš, J.; Lakshmikanth, T.; et al. Normalized Interferon Signatures and Clinical Improvements by IFNAR1 Blocking Antibody (Anifrolumab) in Patients with Type I Interferonopathies. J. Clin. Immunol. 2024, 45, 31. [Google Scholar] [CrossRef] [PubMed]
- Frémond, M.L.; Rodero, M.P.; Jeremiah, N.; Belot, A.; Jeziorski, E.; Duffy, D.; Bessis, D.; Cros, G.; Rice, G.I.; Charbit, B.; et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J. Allergy Clin. Immunol. 2016, 138, 1752–1755. [Google Scholar] [PubMed]
- Sanchez, G.A.M.; Reinhardt, A.; Ramsey, S.; Wittkowski, H.; Hashkes, P.J.; Berkun, Y.; Schalm, S.; Murias, S.; Dare, J.A.; Brown, D.; et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J. Clin. Investig. 2018, 128, 3041–3052. [Google Scholar] [PubMed]
- Sadjadian, P.; Wille, K.; Griesshammer, M. Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations. Cancers 2020, 12, 3132. [Google Scholar] [CrossRef] [PubMed]
- Hebert, A.A.; Bhatia, N.; Del Rosso, J.Q. Molluscum Contagiosum: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps. J. Clin. Aesthet. Dermatol. 2023, 16 (Suppl. S1), S4–S11. [Google Scholar] [PubMed]
- Meza-Romero, R.; Navarrete-Dechent, C.; Downey, C. Molluscum contagiosum: An update and review of new perspectives in etiology, diagnosis, and treatment. Clin. Cosmet. Investig. Dermatol. 2019, 12, 373–381. [Google Scholar] [PubMed]
- Reiss, B.T.; Bouza, L.; Thomas, S.; Suarez, C.D.; Hill, E.R.; Nichols, D.B. The MC160 protein of the molluscum contagiosum virus dampens cGAS/STING-induced interferon-β activation. Exp. Mol. Pathol. 2023, 134, 104876. [Google Scholar] [CrossRef] [PubMed]
- Isufi, D.; Jensen, M.B.; Loft, N.; Skov, L.; Elberling, J.; Alinaghi, F. Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis. JAAD Int. 2024, 18, 106–116. [Google Scholar] [PubMed]
- Abu Rached, N.; Gambichler, T.; Ocker, L.; Schultheis, B.; Susok, L.; Schmidt, W.; Bechara, F.G. Upadacitinib treatment associated with varicella zoster infection complicated by haemophagocytic lymphohistiocytosis in a patient with severe hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 2024, 38, e139–e141. [Google Scholar] [CrossRef] [PubMed]
- Wong, G.N.; Lee, S.; Foley, P. A case of widespread molluscum contagiosum caused by baricitinib, a Janus kinase inhibitor. Australas. J. Dermatol. 2019, 60, e334–e335. [Google Scholar] [PubMed]
- De Luca, E.; Gori, N.; Chiricozzi, A.; Di Stefani, A.; Peris, K. Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib. J. Dermatolog Treat. 2022, 33, 3068–3069. [Google Scholar] [PubMed]
- Kawano, N.; Shiratori, T.; Kawada, A. Case of molluscum contagiosum of an aged female in association with the use of upadacitinib. J. Dermatol. 2022, 49, e171–e172. [Google Scholar] [PubMed]
- Kinoshita, M.; Ogawa, Y.; Kawamura, T.; Kirito, K.; Shimada, S. Case of disseminated molluscum contagiosum caused by ruxolitinib, a Janus kinase 1 and 2 inhibitor. J. Dermatol. 2016, 43, 1387–1388. [Google Scholar] [PubMed]
- Lamberg, O.; Pandher, K.; Troost, J.P.; Lim, H.W. Long-term adverse event risks of oral JAK inhibitors versus immunomodulators: A literature review. Arch. Dermatol. Res. 2024, 317, 109. [Google Scholar] [CrossRef] [PubMed]
- Gambichler, T.; Reuther, J.; Scheel, C.H.; Becker, J.C. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. J. Immunother. Cancer 2020, 8, e001145, Erratum in J. Immunother. Cancer 2021, 9, 1. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gambichler, T.; Devrim, Y.; Susok, L. Stimulator of InterferoN Genes (STING)-Associated Vasculopathy with Onset in Infancy Syndrome (SAVI) Associated with Disseminated Molluscum Contagiosum Under Baricitinib Treatment. Dermato 2025, 5, 6. https://doi.org/10.3390/dermato5020006
Gambichler T, Devrim Y, Susok L. Stimulator of InterferoN Genes (STING)-Associated Vasculopathy with Onset in Infancy Syndrome (SAVI) Associated with Disseminated Molluscum Contagiosum Under Baricitinib Treatment. Dermato. 2025; 5(2):6. https://doi.org/10.3390/dermato5020006
Chicago/Turabian StyleGambichler, Thilo, Yusa Devrim, and Laura Susok. 2025. "Stimulator of InterferoN Genes (STING)-Associated Vasculopathy with Onset in Infancy Syndrome (SAVI) Associated with Disseminated Molluscum Contagiosum Under Baricitinib Treatment" Dermato 5, no. 2: 6. https://doi.org/10.3390/dermato5020006
APA StyleGambichler, T., Devrim, Y., & Susok, L. (2025). Stimulator of InterferoN Genes (STING)-Associated Vasculopathy with Onset in Infancy Syndrome (SAVI) Associated with Disseminated Molluscum Contagiosum Under Baricitinib Treatment. Dermato, 5(2), 6. https://doi.org/10.3390/dermato5020006